ERBB2 and breast carcinoma: mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt; breast cancer.